These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 12806973

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 23. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 24. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H.
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM.
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [Abstract] [Full Text] [Related]

  • 32. Equivalent antihypertensive effects of combination therapy using diuretic + calcium antagonist compared with diuretic + ACE inhibitor.
    Elliott WJ, Polascik TB, Murphy MB.
    J Hum Hypertens; 1990 Dec; 4(6):717-23. PubMed ID: 2096214
    [Abstract] [Full Text] [Related]

  • 33. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
    Kato J, Yokota N, Tamaki N, Kariya S, Kita T, Ayabe T, Eto T, Kitamura K.
    Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
    [Abstract] [Full Text] [Related]

  • 37. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 38. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Jun; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R, Tonolo G.
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [Abstract] [Full Text] [Related]

  • 40. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
    Kidney Blood Press Res; 2009 Nov; 32(4):268-75. PubMed ID: 19776644
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.